CL2018001488A1 - Formulación farmacéutica acuosa del anticuerpo anti-pd-l1 avelumab - Google Patents

Formulación farmacéutica acuosa del anticuerpo anti-pd-l1 avelumab

Info

Publication number
CL2018001488A1
CL2018001488A1 CL2018001488A CL2018001488A CL2018001488A1 CL 2018001488 A1 CL2018001488 A1 CL 2018001488A1 CL 2018001488 A CL2018001488 A CL 2018001488A CL 2018001488 A CL2018001488 A CL 2018001488A CL 2018001488 A1 CL2018001488 A1 CL 2018001488A1
Authority
CL
Chile
Prior art keywords
pharmaceutical formulation
aqueous pharmaceutical
antibody
avelumab
avelumab antibody
Prior art date
Application number
CL2018001488A
Other languages
English (en)
Inventor
Gianluca Rinaldi
Rio Alessandra Del
Silvia Fratarcangeli
Senta Voss
Markus Weigandt
Original Assignee
Pfizer
Merck Patent Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=54838201&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2018001488(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pfizer, Merck Patent Gmbh filed Critical Pfizer
Publication of CL2018001488A1 publication Critical patent/CL2018001488A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)

Abstract

LA PRESENTE INVENCIÓN SE REFIERE A UNA FORMULACIÓN DE ANTICUERPO ANTI-PD-L-1 NOVEDOSA. EN PARTICULAR, LA INVENCIÓN SE REFIERE A UNA FORMULACIÓN FARMACÉUTICA ACUOSA DEL ANTICUERPO ANTI-PD-L1 AVELUMAB.
CL2018001488A 2015-12-07 2018-06-04 Formulación farmacéutica acuosa del anticuerpo anti-pd-l1 avelumab CL2018001488A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP15198233 2015-12-07

Publications (1)

Publication Number Publication Date
CL2018001488A1 true CL2018001488A1 (es) 2018-09-14

Family

ID=54838201

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2018001488A CL2018001488A1 (es) 2015-12-07 2018-06-04 Formulación farmacéutica acuosa del anticuerpo anti-pd-l1 avelumab

Country Status (35)

Country Link
US (2) US11058769B2 (es)
EP (2) EP3747466A1 (es)
JP (1) JP6925337B2 (es)
KR (1) KR20180085801A (es)
CN (1) CN108367072B (es)
AR (1) AR107014A1 (es)
AU (1) AU2016368099C1 (es)
BR (1) BR112018010211A2 (es)
CA (1) CA3007481C (es)
CL (1) CL2018001488A1 (es)
CO (1) CO2018005525A2 (es)
CY (1) CY1123358T1 (es)
DK (1) DK3386541T3 (es)
EA (1) EA201891339A1 (es)
ES (1) ES2823279T3 (es)
HK (1) HK1257781A1 (es)
HR (1) HRP20201573T1 (es)
HU (1) HUE050811T2 (es)
IL (1) IL259563B (es)
LT (1) LT3386541T (es)
MX (1) MX2018006875A (es)
MY (1) MY195681A (es)
NZ (1) NZ743964A (es)
PE (1) PE20181400A1 (es)
PH (1) PH12018500894A1 (es)
PL (1) PL3386541T3 (es)
PT (1) PT3386541T (es)
RS (1) RS61029B1 (es)
SA (1) SA518391743B1 (es)
SG (1) SG11201804758QA (es)
SI (1) SI3386541T1 (es)
TW (1) TWI630917B (es)
UA (1) UA123270C2 (es)
WO (1) WO2017097407A1 (es)
ZA (1) ZA201804534B (es)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10851165B2 (en) 2014-10-14 2020-12-01 Novartis Ag Antibody molecules to PD-L1 and methods of treating cancer

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2856895C (en) * 2011-11-28 2021-10-26 Merck Patent Gmbh Anti-pd-l1 antibodies and uses thereof
WO2015048312A1 (en) 2013-09-26 2015-04-02 Costim Pharmaceuticals Inc. Methods for treating hematologic cancers
JOP20200094A1 (ar) 2014-01-24 2017-06-16 Dana Farber Cancer Inst Inc جزيئات جسم مضاد لـ pd-1 واستخداماتها
JOP20200096A1 (ar) 2014-01-31 2017-06-16 Children’S Medical Center Corp جزيئات جسم مضاد لـ tim-3 واستخداماتها
RU2718914C2 (ru) 2014-09-13 2020-04-15 Новартис Аг Сочетанные способы лечения с использованием ингибиторов alk
SG11201707383PA (en) 2015-03-13 2017-10-30 Cytomx Therapeutics Inc Anti-pdl1 antibodies, activatable anti-pdl1 antibodies, and methods of use thereof
DK3386541T3 (da) 2015-12-07 2020-09-28 Merck Patent Gmbh Vandig farmaceutisk formulering omfattende anti-pd-1-antistof avelumab
CN113773387B (zh) 2016-06-13 2024-06-21 天境生物科技(上海)有限公司 Pd-l1抗体及其用途
AU2017339856A1 (en) 2016-10-06 2019-05-23 Merck Patent Gmbh Dosing regimen of avelumab for the treatment of cancer
BR112019018401A2 (pt) * 2017-03-06 2020-04-07 Merck Patent Gmbh formulação aquosa de anticorpo anti-pd-l1
JP2020522486A (ja) 2017-06-01 2020-07-30 サイトメックス セラピューティクス インコーポレイテッド 活性化可能抗ｐｄｌ１抗体、およびその使用方法
CN111246886B (zh) * 2017-11-02 2022-03-15 正大天晴药业集团股份有限公司 一种抗pd-l1人源化单克隆抗体的药物组合物
CN112041348B (zh) 2018-07-25 2023-09-22 天境生物科技(上海)有限公司 抗cd73抗pd-l1双特异性抗体
WO2020060192A1 (ko) * 2018-09-18 2020-03-26 삼성바이오에피스 주식회사 고농도의 계면활성제를 포함하는 트라스투주맙 안정화 액체 제제
KR20210096640A (ko) * 2018-11-29 2021-08-05 하버 바이오메드 테라푸틱스 리미티드 항-pd-l1 항체 제제
PE20212185A1 (es) 2019-02-18 2021-11-11 Lilly Co Eli Formulacion de anticuerpos terapeuticos
CN114040777A (zh) * 2019-06-25 2022-02-11 信达生物制药(苏州)有限公司 包含抗cd47/pd-l1双特异性抗体的制剂及其制备方法和用途
CN111420049A (zh) * 2019-08-22 2020-07-17 Biocad股份公司 抗-pd1抗体prolgolimab的水性药物组合物及其应用
EP4074338A4 (en) * 2019-12-13 2024-03-06 Samsung Bioepis Co., Ltd. STABLE PHARMACEUTICAL ANTI-PD-1 ANTIBODY PREPARATION
AU2022302143A1 (en) 2021-07-02 2024-01-18 Venugopalareddy BOMMIREDDYVENKATA Compositions and methods for treating cancers
AU2022340804A1 (en) 2021-08-31 2024-03-21 Gennao Bio, Inc. Compositions and methods for treating cancers

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO3000B1 (ar) * 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
PL1934236T3 (pl) 2005-09-02 2013-04-30 Glycomimetics Inc Heterobifunkcjonalne inhibitory pan-selektyny
CA2634547C (en) * 2005-12-20 2016-10-11 Bristol-Myers Squibb Company Stable ctla4 formulation for subcutaneous administration
WO2009126556A1 (en) 2008-04-08 2009-10-15 Glycomimetics, Inc. Pan-selectin inhibitor with enhanced pharmacokinetic activity
KR20210060670A (ko) * 2008-12-09 2021-05-26 제넨테크, 인크. 항-ｐｄ-ｌ１ 항체 및 ｔ 세포 기능을 향상시키기 위한 그의 용도
EP2196476A1 (en) * 2008-12-10 2010-06-16 Novartis Ag Antibody formulation
AU2010338305A1 (en) * 2009-12-29 2012-05-24 F. Hoffmann-La Roche Ag Antibody formulation
WO2012037034A1 (en) 2010-09-14 2012-03-22 Glycomimetics, Inc. E-selectin antagonists
JP6014116B2 (ja) * 2011-03-31 2016-10-25 メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． ヒト・プログラム死受容体ｐｄ−１に対する抗体の安定製剤および関連治療
CA2856895C (en) * 2011-11-28 2021-10-26 Merck Patent Gmbh Anti-pd-l1 antibodies and uses thereof
WO2013112438A1 (en) * 2012-01-23 2013-08-01 Regeneron Pharmaceuticals, Inc. Stabilized formulations containing anti-ang2 antibodies
US9216219B2 (en) * 2012-06-12 2015-12-22 Novartis Ag Anti-BAFFR antibody formulation
BR112016006397B1 (pt) 2013-09-27 2024-01-16 Genentech, Inc Formulações de anticorpo de anti-pdl1, seu uso, artigo de fabricação e composição
WO2015057910A1 (en) * 2013-10-16 2015-04-23 Oncobiologics, Inc. Buffer formulations for enhanced antibody stability
JP2017515859A (ja) * 2014-05-15 2017-06-15 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ 抗ｐｄ−１抗体と他の抗癌剤の組み合わせを使用する肺癌の処置
CN105085680A (zh) * 2014-05-23 2015-11-25 复旦大学 人源化抗PD-1及c-MET双特异性抗体及其制备方法和应用
IL278423B2 (en) 2015-02-26 2024-04-01 Merck Patent Gmbh Fidi-1 / Fidi-AL1 inhibitors for cancer treatment
WO2016181349A1 (en) 2015-05-14 2016-11-17 Pfizer Inc. Combinations comprising a pyrrolidine-2,5-dione ido1 inhibitor and an anti-body
MX2017015937A (es) 2015-06-08 2018-12-11 Genentech Inc Métodos de tratamiento del cáncer con anticuerpos anti-ox40 y antagonistas de unión al eje de pd-1.
WO2016205277A1 (en) 2015-06-16 2016-12-22 Merck Patent Gmbh Pd-l1 antagonist combination treatments
JP2018529719A (ja) 2015-09-30 2018-10-11 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ Ｇｅｓｅｌｌｓｃｈａｆｔ ｍｉｔ ｂｅｓｃｈｒａｅｎｋｔｅｒ Ｈａｆｔｕｎｇ Ａｌｋ陰性がんを処置するためのｐｄ−１系結合アンタゴニストおよびａｌｋ阻害剤の組合せ
DK3386541T3 (da) 2015-12-07 2020-09-28 Merck Patent Gmbh Vandig farmaceutisk formulering omfattende anti-pd-1-antistof avelumab
BR112019018401A2 (pt) 2017-03-06 2020-04-07 Merck Patent Gmbh formulação aquosa de anticorpo anti-pd-l1

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10851165B2 (en) 2014-10-14 2020-12-01 Novartis Ag Antibody molecules to PD-L1 and methods of treating cancer

Also Published As

Publication number Publication date
PH12018500894A1 (en) 2018-11-05
MX2018006875A (es) 2018-11-09
UA123270C2 (uk) 2021-03-10
NZ743964A (en) 2023-03-31
AR107014A1 (es) 2018-03-14
CA3007481C (en) 2024-01-30
KR20180085801A (ko) 2018-07-27
LT3386541T (lt) 2020-10-26
EP3386541A1 (en) 2018-10-17
HK1257781A1 (zh) 2019-10-25
RS61029B1 (sr) 2020-12-31
AU2016368099C1 (en) 2023-10-12
JP6925337B2 (ja) 2021-08-25
CN108367072B (zh) 2022-12-27
PL3386541T3 (pl) 2021-04-06
SI3386541T1 (sl) 2020-11-30
US11058769B2 (en) 2021-07-13
ES2823279T3 (es) 2021-05-06
DK3386541T3 (da) 2020-09-28
IL259563A (en) 2018-07-31
CN108367072A (zh) 2018-08-03
CY1123358T1 (el) 2021-12-31
AU2016368099B2 (en) 2023-03-09
WO2017097407A1 (en) 2017-06-15
US20180369377A1 (en) 2018-12-27
PT3386541T (pt) 2020-10-12
TWI630917B (zh) 2018-08-01
SA518391743B1 (ar) 2022-12-01
EP3747466A1 (en) 2020-12-09
SG11201804758QA (en) 2018-07-30
EA201891339A1 (ru) 2019-01-31
TW201725051A (zh) 2017-07-16
JP2018536676A (ja) 2018-12-13
BR112018010211A2 (pt) 2019-02-05
IL259563B (en) 2021-05-31
MY195681A (en) 2023-02-03
US20210100903A1 (en) 2021-04-08
AU2016368099A1 (en) 2018-07-19
PE20181400A1 (es) 2018-09-07
EP3386541B1 (en) 2020-07-08
ZA201804534B (en) 2020-11-25
CA3007481A1 (en) 2017-06-15
HUE050811T2 (hu) 2021-01-28
CO2018005525A2 (es) 2018-08-10
HRP20201573T1 (hr) 2020-12-11

Similar Documents

Publication Publication Date Title
CL2018001488A1 (es) Formulación farmacéutica acuosa del anticuerpo anti-pd-l1 avelumab
FR21C1030I2 (fr) Conjugué anticorps anti-her2-médicament
CL2016002455A1 (es) Anticuerpos multiespecíficos.
MA53297A (fr) Anticorps anti-icos
DK3229810T3 (da) Phospholipid-ether-analoger som kræftrammende lægemiddelvehikler
BR112016023628A2 (pt) composições farmacêuticas.
BR112016030284A2 (pt) Formulações, seu uso ou produção de detergentes de lavagem de louça e sua produção
MX2019010367A (es) Formulacion acuosa de anticuerpo anti ligando 1 de muerte programada (pd-l1).
BR112017009792A2 (pt) anticorpos anti-pdgf-b e métodos de uso
BR112018002382A8 (pt) Novos anticorpos anti-gvpi humano e usos dos mesmos
CU20170012A7 (es) Anticuerpos anti proteína similar a angiopoyetina 4
AR101671A1 (es) Anticuerpos anti proteína similar a angiopoyetina-4 (angptl4) y métodos de uso
GT201600252A (es) Derivados de naftiridinadiona
DK3216451T3 (da) Oftalmisk vandig sammensætning
CO2017007316A2 (es) Formulación farmacéutica
DK3247394T3 (da) Farmaceutisk formulering omfattende anti-egfr-antistof
DK3199160T3 (da) Vandig sammensætning
MA47168A (fr) Sous-vêtement
EA201991993A1 (ru) Применение фенилкреатина в качестве ноотропного агента
BR112016027254A2 (pt) Complexo de quitina-glucano, sua preparação e utilizações
TH1601000953A (th) พอลิเพพไทด์ที่เสถียรที่จับเกาะกับคอมพลีเมนต์ c5 ของมนุษย์
TH1601003749A (th) แอนทิบอดีชนิดโมโนคลอนัลที่ทำให้เป็นกลาง แอนทิ-il-33 ของมนุษย์
TH1501005169A (th) ยาผสมทางเภสัชกรรม
FR3027221B1 (fr) Gel aqueux cosmetique
TH1501007100A (th) องค์ประกอบทางเภสัชกรรม, การเตรียม และการใช้ของมัน